Extract

A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).

Inclusion criteria

• pulmonary arterial hypertension

Country

• Austria
• Belgium
• Canada
• France
• Germany
• Italy
• Japan
• Korea, Republic of
• Netherlands
• Spain
• Sweden
• Switzerland
• United Kingdom
• United States

Links

• ictrp
• nct